Simplified MIPI Calculator
Simplified prognostic index for advanced-stage mantle cell lymphoma
Applies at the time of first treatment.
1. Evaluate each risk factor to calculate simplified MIPI score
2. Determine risk category and prognosis
|s-MIPI score||s-MIPI risk category||Median TTF (years)1||5 year OS (%)1|
|0 - 3||Low risk||6.3||81|
|4 or 5||Intermediate risk||3.8||63|
|6 or higher||High risk||1.4||35|
The Mantle Cell Lymphoma International Prognostic Index (MIPI) derives from multivariate analysis of survival of 455 patients with mantle cell lymphoma treated between 1996 and 2004.2 Patients were treated with chemotherapies including CHOP, R-CHOP and MCP.
Whereas the full MIPI and MIPIb use complex formulas to treat prognostic factors as continuous variables, the simplified MIPI assigns each factor a score from 0 to 3. An overall risk score is determined by summing of the ratings for each factor.
In an analysis of a large independent cohort of patients treated within clinical trials, s-MIPI was recommended over the MIPI for routine clinical use, as it showed comparable prognostic performance while being easier to use.1 The s-MIPI retains prognostic relevance in patients uniformly treated with intensive chemoimmunotherapy followed by autologous stem cell transplantation.3
LDH: lactate dehydrogenase
MIPI: mantle cell lymphoma international prognostic index
OS: overall survival
TTF: time to treatment failure
- Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014; 32: 1338-1346.
- Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
- Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530-1533.